StimCell Enegetics

StimCell Enegetics Net Margin

The Net Profit Margin of StimCell Enegetics (STME) as of Oct 21, 2026 is -17,923.32 %. In the previous year, Net Profit Margin was -11,498.42 % — a change of 55.88% (lower).

Net Margin

-17,923.32 %

YoY

55.88%

Last updated:

Net Profit Margin of StimCell Enegetics is 2023 -17,923.32 % . Net Profit Margin of StimCell Enegetics was 2022 -11,498.42 % . It decreases by 55.88% lower compared to the previous year.

For StimCell Enegetics, the net margin of -17,923.3% is down versus -962.9% a few years ago.

The StimCell Enegetics Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2015
-2,823.44 USD
Jan 1, 2016
-5,851.51 USD
Jan 1, 2017
-20,087.56 USD
Jan 1, 2019
-962.91 USD
Jan 1, 2020
-1,140.32 USD
Jan 1, 2021
-15,017.91 USD
Jan 1, 2022
-11,498.42 USD
Jan 1, 2023
-17,923.32 USD
The StimCell Enegetics Net Margin history
YEARNet MarginYoY
-17,923.32 %+55.88%
-11,498.42 %-23.44%
-15,017.91 %+1,216.99%
-1,140.32 %+18.42%
-962.91 %-95.21%
-20,087.56 %+243.29%
-5,851.51 %+107.25%
-2,823.44 %+6,395.73%
-43.47 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

StimCell Enegetics Stock analysis

What does StimCell Enegetics do? Cell MedX Corp. makes money through its subsidiary Avyonce Cosmedics Inc., which resells spa technology and equipment to the beauty and wellness industry. Avyonce also markets eBalance Technology, used for micro current treatments targeting diabetes and related ailments, and conducts observational studies with this technology. The company provides continuing education for estheticians and healthcare professionals in medical aesthetics. Avyonce Cosmedics Inc. serves the beauty and wellness industry, focusing on professionals who use spa technology and equipment. The firm develops a family of devices based on eBalance Technology, which is applied in treatments for diabetes and related conditions. This technology is central to Avyonce's product offerings and educational services. Cell MedX Corp. operates as a development stage company with no full-time employees, relying on its subsidiary Avyonce to drive revenue. The company's business model centers on the commercialization of eBalance Technology through product sales, educational programs, and observational studies in the medical aesthetics sector. StimCell Enegetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about StimCell Enegetics stock

Net Profit Margin of StimCell Enegetics is -17,923.32 % in 2023.

Net Profit Margin of StimCell Enegetics changed from -11,498.42 % to -17,923.32 %, representing a 55.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin StimCell Enegetics since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's StimCell Enegetics with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — StimCell Enegetics

All Key Metrics — StimCell Enegetics